Plain-English translation of NCT06700395 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This clinical trial is testing a new medication called TQB2029 for Injection in people with multiple myeloma, a cancer of blood cells. The study will first figure out the right dose and how well patients tolerate the medication, then test whether it actually helps shrink tumors. About 136 people in China will participate in this research.
Multiple myeloma is a serious blood cancer that needs better treatment options. This medication represents a new approach, and researchers want to understand the safest dose and whether it can help patients with this disease.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the study medication on a schedule, with each treatment cycle lasting 28 days. The study has two phases: first, researchers will gradually increase doses to find the safest amount, then they will test that dose in more patients to see if it works against the cancer. Throughout the study, you'll have regular blood tests and imaging scans to check how you're responding and monitor for any side effects.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China